Navigation Links
Watson Provides Update on Generic Lidoderm® Application
Date:2/3/2012

PARSIPPANY, N.J., Feb. 3, 2012 /PRNewswire/ -- In response to investment community speculation following release of the transcript of a pre-trial conference call related to its Lidoderm® patent challenge, Watson Pharmaceuticals, Inc. (NYSE: WPI) today issued the following statement:

"Watson's abbreviated new drug application (ANDA) for a generic version of Lidoderm remains on track. We believe questions related to the site where a biostudy supporting the ANDA was conducted have been addressed to FDA's satisfaction.  We continue to work closely with the FDA with the goal of timely approval. Watson has made public comments throughout the year regarding our Lidoderm application, including most recently at our analyst day on January 24th, where the Company restated our confidence that a tentative approval for generic Lidoderm will be received prior to the 30-month stay expiry on July 15, 2012.

"In order not to affect the pending patent litigation trial, it is our policy not to comment during litigation. Therefore, we will not provide additional comment on details that may arise during the trial."

About Watson Pharmaceuticals, Inc.Watson Pharmaceuticals, Inc., is a leading integrated global pharmaceutical company. The Company is engaged in the development and distribution of generic pharmaceuticals and specialized branded pharmaceutical products focused on Urology and Women's Health. Watson has operations in many of the world's established and growing international markets.

For press release and other company information, visit Watson Pharmaceuticals' Web site at http://www.watson.com.

Forward-Looking Statement Statements contained in this press release that refer to Watson's estimated or anticipated future results or other non-historical facts are forward-looking statements that reflect W
'/>"/>

SOURCE Watson Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related medicine technology :

1. Watson Launches Generic Biaxin(R) XL
2. Watson Announces Positive Results From Its Pivotal Study of Oxybutynin Topical Gel for the Treatment of Overactive Bladder
3. Watson Announces Silodosin NDA Accepted for Filing by FDA for the Treatment of Benign Prostatic Hyperplasia
4. Watson Announces Positive Data for Its New Investigational Products for Benign Prostatic Hyperplasia and Overactive Bladder
5. Watson Announces United States Availability of RAPAFLO(TM) (silodosin), a Novel New Treatment in Benign Prostatic Hyperplasia (BPH)
6. Watson and Barr Settle Lawsuit Over Oxytrol(R)
7. Watson to Host Conference Call and Webcast to Discuss Fourth Quarter 2009 Earnings and 2010 Outlook
8. Watson Completes Acquisition of Eden Biodesign
9. Watson to Present at Credit Suisse Healthcare Conference
10. Watson Announces New Program to Help Promote Good Bone Health in Advanced Prostate Cancer Patients on Long-Term Androgen Deprivation Therapy
11. Watson Files FDA Application for Generic Rozerem(R)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/22/2012)...  Avaxia Biologics, Inc., a privately-held biotechnology ... locally within the gastrointestinal tract, announced today ... 8,182,818, entitled "Methods of Using Anti-TNF Antibodies ... Tract." This patent provides broad ... to treat radiation induced damage to the ...
(Date:5/22/2012)...  Upsher-Smith Laboratories, Inc. announced today that Senior ... McKesson Branded Pharmaceutical Representative of the Year Award ... Las Vegas, NV on May 8, 2012.  The ... President of Purchasing at McKesson.  ... CA-based McKesson, one of the largest pharmaceutical distributors ...
(Date:5/22/2012)... -- APEX BIOSTRATEGISTS, A FULL SERVICE ADVISORY FIRM, LED ... SALE BY NPE SYSTEMS, INC. AND BLUE OCEAN BIOMEDICAL, ... NPE AND BLUE OCEAN WERE TECHNOLOGY LEADERS IN THE ... TISSUE TESTING FOR PATIENT MONITORING AND FOR DRUG RESEARCH. ... OF FLOW CYTOMETRY SYSTEMS TO HOSPITALS AND TESTING LABS ...
Breaking Medicine Technology:Avaxia Biologics is Awarded U.S. Patent for Method to Treat Radiation Damage to the Digestive Tract and Mucositis Caused by Radiation 2Dave Zitnak Of Upsher-Smith Laboratories Named Branded Representative Of The Year By McKesson Corporation 2Apex BioStrategists Advises On Flow Cytometry Sale To Coulter 2Cedars Sinai awarded 241 9 million from CIRM to develop stem cell treatments for osteoporosis 76539 1Cedars Sinai awarded 241 9 million from CIRM to develop stem cell treatments for osteoporosis 76539 2Medivir Interim Report 1 January 30 September 2010 12006 1Medivir Interim Report 1 January 30 September 2010 12006 2Medivir Interim Report 1 January 30 September 2010 12006 3Medivir Interim Report 1 January 30 September 2010 12006 4Medivir Interim Report 1 January 30 September 2010 12006 5Medivir Interim Report 1 January 30 September 2010 12006 6Medivir Interim Report 1 January 30 September 2010 12006 7Medivir Interim Report 1 January 30 September 2010 12006 8Essilor Third Quarter 2010 Report 12004 1Essilor Third Quarter 2010 Report 12004 2Essilor Third Quarter 2010 Report 12004 3Essilor Third Quarter 2010 Report 12004 4Essilor Third Quarter 2010 Report 12004 5Essilor Third Quarter 2010 Report 12004 6Essilor Third Quarter 2010 Report 12004 7Essilor Third Quarter 2010 Report 12004 8Essilor Third Quarter 2010 Report 12004 9Essilor Third Quarter 2010 Report 12004 10
... Nektar,Therapeutics (Nasdaq: NKTR ) today ... study,for NKTR-118 (PEG-naloxol), an oral treatment being ... clinical manifestations of,opioid-induced bowel dysfunction (OBD). The ... safety and tolerability,of NKTR-118 in patients experiencing ...
... Data and Emerging Clinical Practice Experience Support ... HYLENEX Efficacy and ... Inc.,(Nasdaq: HALO ), a biopharmaceutical company developing and commercializing,products ... of the INFUSE-LR clinical trial results in the Journal,of Palliative ...
Other Medicine Technology:Nektar Commences Phase 2 Trial of NKTR-118 (oral PEG-naloxol) Evaluating Efficacy and Safety as Treatment for Opioid-Induced Bowel Dysfunction 2Nektar Commences Phase 2 Trial of NKTR-118 (oral PEG-naloxol) Evaluating Efficacy and Safety as Treatment for Opioid-Induced Bowel Dysfunction 3Nektar Commences Phase 2 Trial of NKTR-118 (oral PEG-naloxol) Evaluating Efficacy and Safety as Treatment for Opioid-Induced Bowel Dysfunction 4Nektar Commences Phase 2 Trial of NKTR-118 (oral PEG-naloxol) Evaluating Efficacy and Safety as Treatment for Opioid-Induced Bowel Dysfunction 5Halozyme Therapeutics Announces Peer-Reviewed Publications of the INFUSE-LR Clinical Trial Results and Clinical Practice Experience With Hylenex 2Halozyme Therapeutics Announces Peer-Reviewed Publications of the INFUSE-LR Clinical Trial Results and Clinical Practice Experience With Hylenex 3Halozyme Therapeutics Announces Peer-Reviewed Publications of the INFUSE-LR Clinical Trial Results and Clinical Practice Experience With Hylenex 4Halozyme Therapeutics Announces Peer-Reviewed Publications of the INFUSE-LR Clinical Trial Results and Clinical Practice Experience With Hylenex 5
(Date:5/22/2012)... Large randomized controlled trials (RCTs) are critical for ... Yet Canada provides scant support for these studies ... in CMAJ ( Canadian Medical Association ... and Hamilton Health Sciences, Hamilton, Ontario, with Dr. ... the analysis and appendix that Canada should provide ...
(Date:5/22/2012)... The University of Kentucky Markey Cancer Center has ... blood and bone marrow disease often caused by chemotherapy ... Edward P. Evans Foundation, along with a $1.25 million ... , The Evans Foundation grant will fund five research ... one at Cincinnati Children,s Hospital, and one at the ...
(Date:5/22/2012)... 2012) -- Researchers at Barrow Neurological Institute at ... how and why the public perceives some magic ... implications in military tactics, marketing and sports. , ... Neuroscience, and Stephen Macknik, PhD, of Barrow,s Laboratory ... research into magic and illusions. Their most recent ...
(Date:5/22/2012)... , , TUESDAY, May 22 (HealthDay News) -- Two preliminary ... both the detection and treatment of pancreatic cancer. ... said they have fashioned a vaccine that, in early ... attacking cancer cells. The team -- from Case ... Cancer Center at University Hospitals Case Medical Center in ...
(Date:5/22/2012)... (May 22, 2012) -- Up to half of all prostate ... new "fusion" gene and formation of its unique protein -- ... growth. Now, Weill Cornell Medical College researchers have found that ... up in a little ball known as a chromatin, is ... thrown on thousands of genes, turning them on or off ...
Breaking Medicine News(10 mins):Health News:Canada should significantly increase its funding of randomized clinical trials 2Health News:Markey receives $6.25 million to study deadly blood and bone marrow disease 2Health News:Markey receives $6.25 million to study deadly blood and bone marrow disease 3Health News:Barrow researchers use magic for discoveries 2Health News:Studies See Advances in Detecting, Treating Pancreatic Cancer 2Health News:Studies See Advances in Detecting, Treating Pancreatic Cancer 3Health News:Studies See Advances in Detecting, Treating Pancreatic Cancer 4Health News:Scientists unravel role of fusion gene in prostate cancer 2Health News:Scientists unravel role of fusion gene in prostate cancer 3Health News:Scientists unravel role of fusion gene in prostate cancer 4
... or incapable of quitting smoking, but are prepared to try ... . ,However, after studying healthcare literature, a team ... been given to this alternative of cutting down the number ... at smokers has been at helping them to stop smoking ...
... cheap. But the new bionic hand, developed by a Scottish engineer, is ... ,It can't click its fingers or play the piano but there's ... instance, turn a key in a lock, hold a wine glass ... ,David Gow who works with with Lothian NHS in Scotland and the ...
... that combining a non-pyrethroid insecticide, propoxur, and a ... effective insecticide-repellent synergy against mosquitoes responsible for ... of the two had proved to be much ... respective properties. Mosquito nets soaked with this mixture ...
... Mwanawasa on Thursday opened a 10 million dollar specialist cancer ... for the first time . ,Mwanawasa said the ... in the number of cancer patients in Zambia who have ... the state of an average 10,000 dollars per person. ...
... Madras Diabetes Research Foundation (MDRF), in collaboration with the ... Index Testing Centre in Chennai . ,For ... and its products, this is a significant development. For ... the Glycemic Index (the metabolic speed at which food ...
... of medical negligence has been registered against the premier institute ... fine of Rs five lakhs by the State Consumer Commission ... guilty of wrongly diagnosing a woman as cancer patient and ... ago. ,The Commission Bench headed by Justice J ...
Other Medicine News:Health News:Chain Smokers Prepared to Lessen Their Daily Cigs Rather Than Quitting 2Health News:Scottish Engineer Devises Versatile Hand 2Health News:Insecticide and Repellent Combo Effective in Eliminating Malarial Mosquitoes 2Health News:A Centre for Glycemic Index Testing Opened in Chennai 2Health News:AIIMS Fined Rs 5 Lakhs for Negligence 2
The CapSureFix line of pacing leads combines the benefits of steroid-eluting technology with screw-in active fixation, to allow long-lasting, low-threshold delivery of pacing therapies....
... Physique leads are small profile endocardial permanent ... With a lead body size of only ... of 7 F, the Physique lead is ... today. Available in both straight and pre-formed ...
Used with permanent pacing leads....
...
Medicine Products: